Flamicort 4mg tablets
Ingredients in every tablet
Each package contains
|ATC Level 1||H - Systemic hormonal preparations; excluding sex hormones and insulins|
|ATC Level 2||H02 - Corticosteroids for Systemic Use|
|ATC Level 3||H02A - Corticosteroids for Systemic Use; Plain|
18 YEARS OLD AND ABOVE
Initial dose: 4-48 mg per day, depending on the specific disease entity being treated.
0 TO 18 YEARS OLD
The recommended dosage should be governed by the same considerations rather than by strict adherence to the ratio indicated by age or body weight. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
After a favorable response is noted, maintenance dosage must be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
TRANSFER PATIENTS FROM OTHER CORTICOSTEROIDS
Substitute triamcinolone 4 mg initially in place of each cortisone 25 mg, hydrocortisone 20 mg, prednisone 5 mg, prednisolone 5 mg, methylprednisolone 4 mg, dexamethasone 0.75 mg, betamethasone 0.6 mg, paramethasone 2 mg. Thereafter, dosage should be adjusted according to individual response.
Treatment for the following conditions:
Primary or secondary adrenocortical insufficiency (hydrocortisones or cortisones are the drugs of choice although synthetic analogs may be used in conjunction with mineralocorticoids where applicable, mineralocorticoid supplementation is of particular importance when treating this condition in infants); congenital adrenal hyperplasia; nonsuppurative thyroiditis; and hypercalcemia associated with cancer.
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in psoriatic arthritis; rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis, post-traumatic osteoarthritis; synovitis of osteoarthritis; and epicondylitis.
For use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus and acute rheumatic carditis.
Pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides and severe psoriasis.
For the control of seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, angioedema and urticaria when they are severe or incapacitating and intractable to adequate trials of conventional treatment.
Severe, acute and chronic allergic and inflammatory processes involving the eye and its associated anatomic parts e.g., allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis and sympathetic ophthalmia.
Symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when concurrently accompanied by appropriate antituberculous chemotherapy, pulmonary emphysema where bronchospasm or bronchial edema plays a significant role and diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome).
Idiopathic and secondary thrombocytopenia in Adults, acquired (auto-immune) hemolytic anemia, erythroblastopenia (RBC anemia) and congenital (erythroid) hypoplastic anemia.
For palliative management of leukemias and lymphomas in Adults and acute leukemia in childhood.
To induce diuresis or remission of proteinuria in the nephrotic syndrome (non-uremic, the idiopathic type or that which is due to lupus erythematosus) and, in conjunction with diuretic agents, to induce diuresis in refractory congestive heart failure and in cirrhosis of the liver with refractory ascites.
To tide the patient over a critical period of the disease in ulcerative colitis, regional enteritis and intractable sprue.
Dental postoperative inflammatory reactions and tuberculous meningitis with subarachnoid block or impending block when concurrently accompanied by appropriate antituberculous chemotherapy.